CMS approves off-label chemotherapy compendium
Executive Summary
CMS will recognize the National Comprehensive Cancer Network Drugs & Biologics Compendium as an approved reference for coverage of off-label uses of cancer drugs and biologics, the agency announces June 5. Local Medicare contractors who process claims for Part B, or physician-administered, drugs would consult the compendia when deciding whether to approve claims. CMS also announces it will formally delete from its list of recognized compendia the American Medical Association Drug Evaluations compendium, which ceased publication in 1996. The decisions represent a first step in CMS' efforts to update its compendia list; decisions in the coming weeks are expected on three other references - Gold Standard's Clinical Pharmacology and Thomson Micromedex's DrugPoints and DrugDex (1"The Pink Sheet" April 14, 2008, p. 15)
You may also be interested in...
CMS Opens Door To More Compendium Oversight In Draft White Paper
A draft white paper examining conflict of interest in the production of drug compendia appears to open the door for more oversight of the publications used for determining coverage of prescription drugs' off-label indications by Medicare and private insurers
CMS Decisions On New Off-Label Chemotherapy Compendia Due By Early July
CMS will issue decisions by early July on the possible addition of four medical compendia as approved references for coverage of off-label uses of cancer drugs and biologicals
Entries Begin To Roll In For 2024 Industry Awards
Entries have now begun rolling in for the Global Generics & Biosimilars Awards, which returns to Milan this October, Free to enter and attend, the ceremony recognizes the top achievements across the generics, biosimilars and value added medicines industries.